+86-13708084407
  export@pu-kang.com            yasmin@pu-kang.com
 
You are here: Home » News

News and Events

2022
DATE
05 - 17
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
OLUMIANT is the first and only JAK inhibitor FDA-approved for the treatment of COVID-19 in certain hospitalized adults requiring various degrees of oxygen support.INDIANAPOLIS, May 11, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today the U.S. Food and
Read More
2022
DATE
05 - 14
FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes
Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trialsWhile not indicated for weight loss, Mounjaro led to significantly greater weight reductions versus comparators in a key secondary endpointMounjaro represents the first new class of diabetes medicines
Read More
2022
DATE
04 - 28
Monodispersed DOTA-PEG–Conjugated Anti-TAG-72 Diabody Has Low Kidney Uptake and High Tumor-to-Blood Ratios Resulting in Improved 64Cu PET
Diabodies are noncovalent dimers of single-chain antibody fragments that retain the avidity of intact IgG but have more favorable blood clearance than intact IgG. Radiometals offer a wide range of half-lives and emissions for matching imaging and therapy requirements and provide facile labeling of c
Read More
2021
DATE
11 - 05
Antibody-Drug Conjugates: The Last Decade
AbstractAn armed antibody (antibody-drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamici
Read More
2021
DATE
10 - 28
Tirzepatide results superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes
Newly published data show that participants maintained A1C and weight control up to two years in SURPASS-4, the largest and longest SURPASS trial completed to dateNo increased cardiovascular risk identified with tirzepatide; hazard ratio of 0.74 observed for MACE-4 events
Read More
2021
DATE
09 - 29
RNA interference (RNAi)
RNA interference (RNAi) is a biological process in which RNA molecules are involved in sequence-specific suppression of gene expression by double-stranded RNA, through translational or transcriptional repression. Historically, RNAi was known by other names, including co-suppression, post-transcripti
Read More
2021
DATE
09 - 29
What are PROTACs and How Do They Treat Diseases?
Around 80% of disease-causing proteins, including key drivers of many cancers and other serious neurological conditions like Alzheimer’s disease, cannot be targeted by currently available therapeutics. These so called “undruggable” proteins lack specific surface areas required for treatments such as
Read More
2021
DATE
09 - 19
SNAC promotes the oral absorption of semaglutide tablets
Abstract: Semaglutide is a polypeptide compound with large molecularweight, hydrophilicity, and low permeability for the treatment of type 2 diabetes and obesity. Semaglutide injection has poor compliance that restricts its use, so semaglutide tablets appear. Semaglutide tablets mainly contain gluca
Read More
2021
DATE
09 - 18
The Latest Research and Development into the Antibody–Drug Conjugate
Source: Takashi Nakada, Kiyoshi Sugihara, Takahiro Jikoh, Yuki Abe, Toshinori Agatsuma ~The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy1. Introduction Traditional chemotherapy has been the predominant modality of
Read More
2021
DATE
03 - 04
Lilly's tirzepatide beats Novo's semaglutide in diabetes phase 3
Another phase 3 clinical trial of Eli Lilly’s tirzepatide in Type 2 diabetics has met its primary endpoint. The dual GIP/GLP-1 agonist beat Novo Nordisk’s semaglutide against multiple measures, although recent data on another dose of the rival drug suggest Lilly has a fight on its hands.
Read More
2021
DATE
01 - 04
CPHI meetings
From the past 10years, Chengdu Pukang had already attend
Read More
2020
DATE
09 - 22
Insulin icodec is coming!
Bagsværd, Denmark, 22 September 2020 – Today, Novo Nordisk announced results from three phase 2 clinical trials for insulin icodec, an investigational once-weekly basal insulin analogue, which were presented during the 56th European Association for the Study of Diabetes (EASD) Annual Meeting 2020.Th
Read More
2020
DATE
04 - 22
Somapacitan Mechanism of Action
Somapacitan is under investigation in clinical trial NCT01706783 (A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults with Growth Hormone Deficiency).
Read More
About Us
Chengdu Pukang has a professional R&D team with first-class technology, rich experience, and innovative ideas, which can meet the various needs of customers from custom synthesis to mass production.
Contact Us
​​​​​​​​​​​​​​No.288 of North Rongtai Avenue,WenJiang district 611137,Chengdu Sichuan
Province,China.
+86-28-63976226
Copyright © 2021 chengdu Pukang Biological Technology Co., Ltd.  Support By Leadong  Sitemap / Private Policy
Leave a Message
Contact us